CRISPR Therapeutics Stock News

CRISPR Therapeutics stock has room to run higher with the biotech's first therapy on the market. Eli Lilly is now the world's biggest drugmaker and has multiple growth drivers.

In the tech space, certain tech stocks stand as front-liners of innovation and strategic brilliance. This article delves into the riveting strategies of three companies that have not merely weathered

The Food and Drug Administration approved the use of Casgevy, a therapy from Vertex Pharmaceuticals and CRISPR Therapeutics that uses CRISPR gene-editing to treat the serious blood disorder transfusio

The U.S. Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals and CRISPR Therapeutics' gene therapy to treat a rare blood disorder requiring regular blood transfusions, in patients 1

Investors who are willing to accept risk can be compensated with more upside potential. CRISPR is in the early stages of rolling out gene therapy products that could be very valuable.

CRISPR passed several major miletones in its quest to bring its first treatment to market. The company has no product revenue, so it's prone to market-driven volatility.

CRISPR Therapeutics recently obtained approval for its gene therapy Casgevy. The therapy could generate close to $4 billion in annual revenue at its peak.

While the technology sector – especially regarding artificial intelligence – may have captured the spotlight, investors ought to consider adding healthcare stocks to their portfolio. If I had to b

Cathie Wood has loaded up her portfolio with tomorrow's potential healthcare game changers. The superstar investor's commitment to innovation helped her flagship fund jump more than 60% last year.

CRISPR Therapeutics AG (CRSP) 42nd Annual J.P. Morgan Healthcare Conference (Transcript)

Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic differences.

CRISPR Therapeutics recently won regulatory approval for its first product. Casgevy, for blood disorders, has the potential to reach blockbuster status.

CRISPR Therapeutics is a gene therapy and gene editing company focused on developing gene-based medicines using CRISPR and Cas9 technologies. The company recently gained approval for Casgevy, a cure f

Betting on healthcare's future via healthcare stocks is one of the safest long-term bets you can make. Though changes and advances happen rapidly, healthcare is one industry that is here to stay.

Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal Drug Administration (FDA) approved a sickle